# Bartolome R Celli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5873063/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 323 papers | 40,949 citations | 4120 87 h-index | 2558 195 g-index |
| 398 all docs | 398 docs citations | 398 times ranked | 22176 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2004, 350, 1005-1012. | 13.9 | 3,409 |
| 2 | Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2007, 356, 775-789. | 13.9 | 2,963 |
| 3 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 557-582. | 2.5 | 2,393 |
| 4 | A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2008, 359, 1543-1554. | 13.9 | 1,969 |
| 5 | American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1390-1413. | 2.5 | 1,644 |
| 6 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164. | 3.1 | 1,223 |
| 7 | Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2015, 373, 111-122. | 13.9 | 974 |
| 8 | Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respiratory Research, 2010, 11, 122. | 1.4 | 952 |
| 9 | Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 155-161. | 2.5 | 946 |
| 10 | Chronic Obstructive Pulmonary Disease Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 598-604. | 2.5 | 898 |
| 11 | Changes in Forced Expiratory Volume in 1 Second over Time in COPD. New England Journal of Medicine, 2011, 365, 1184-1192. | 13.9 | 811 |
| 12 | Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 332-338. | 2.5 | 692 |
| 13 | Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. PLoS ONE, 2012, 7, e37483. | 1.1 | 633 |
| 14 | Outcomes in Patients with Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 325-331. | 2.5 | 589 |
| 15 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. European Respiratory Journal, 2017, 49, 1700214. | 3.1 | 536 |
| 16 | Inspiratory-to-Total Lung Capacity Ratio Predicts Mortality in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 591-597. | 2.5 | 514 |
| 17 | Chronic obstructive pulmonary disease. Nature Reviews Disease Primers, 2015, 1, 15076. | 18.1 | 444 |
| 18 | Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet, The, 2009, 374, 1171-1178. | 6.3 | 430 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet, The, 2016, 387, 1817-1826. | 6.3 | 378 |
| 20 | Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1065-1072. | 2.5 | 353 |
| 21 | Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA - Journal of the American Medical Association, 2016, 315, 672. | 3.8 | 333 |
| 22 | Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respiratory Medicine, 2013, 107, 1376-1384. | 1.3 | 328 |
| 23 | Long-term Controlled Trial of Nocturnal Nasal Positive Pressure Ventilation in Patients With Severe COPD. Chest, 2000, 118, 1582-1590. | 0.4 | 312 |
| 24 | Informe 2017 de la Iniciativa Global para el DiagnÃ³stico, Tratamiento y PrevenciÃ³n de la Enfermedad Pulmonar Obstructiva CrÃ³nica: Resumen Ejecutivo de GOLD. Archivos De Bronconeumologia, 2017, 53, 128-149. | 0.4 | 312 |
| 25 | Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. Respirology, 2017, 22, 575-601. | 1.3 | 299 |
| 26 | Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research, 2009, 10, 59. | 1.4 | 287 |
| 27 | What is asthmaâ^'COPD overlap syndrome? Towards a consensus definition from a round table discussion. European Respiratory Journal, 2016, 48, 664-673. | 3.1 | 287 |
| 28 | Improvement in Resting Inspiratory Capacity and Hyperinflation With Tiotropium in COPD Patients With Increased Static Lung Volumes *. Chest, 2003, 124, 1743-1748. | 0.4 | 278 |
| 29 | Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 913-919. | 2.5 | 266 |
| 30 | Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2019, 381, 1257-1266. | 13.9 | 264 |
| 31 | Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 382-386. | 2.5 | 257 |
| 32 | Distance and Oxygen Desaturation During the 6-min Walk Test as Predictors of Long-term Mortality in Patients With COPD. Chest, 2008, 134, 746-752. | 0.4 | 254 |
| 33 | Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 948-955. | 2.5 | 252 |
| 34 | Prevalence and Progression of Osteoporosis in Patients With COPD. Chest, 2009, 136, 1456-1465. | 0.4 | 240 |
| 35 | Prevention of Acute Exacerbations of COPD. Chest, 2015, 147, 894-942. | 0.4 | 230 |
| 36 | The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respiratory Medicine,the, 2013, 1, 129-136. | 5.2 | 224 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Impact of COPD Exacerbations on Patient-Centered Outcomes. Chest, 2007, 131, 696-704. | 0.4 | 219 |
| 38 | Power of Outcome Measurements to Detect Clinically Significant Changes in Pulmonary Rehabilitation of Patients With COPD. Chest, 2002, 121, 1092-1098. | 0.4 | 214 |
| 39 | Gender and COPD in Patients Attending a Pulmonary Clinic. Chest, 2005, 128, 2012-2016. | 0.4 | 214 |
| 40 | Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD. Chest, 2006, 130, 647-656. | 0.4 | 205 |
| 41 | The 6-Min Walk Distance, Peak Oxygen Uptake, and Mortality in COPD. Chest, 2007, 132, 1778-1785. | 0.4 | 205 |
| 42 | The Progression of Chronic Obstructive Pulmonary Disease Is Heterogeneous. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1015-1021. | 2.5 | 197 |
| 43 | Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2012, 13, 291-297. | 1.2 | 193 |
| 44 | Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 51-57. | 2.5 | 192 |
| 45 | At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1540-1551. | 2.5 | 185 |
| 46 | Benralizumab for the Prevention of COPD Exacerbations. New England Journal of Medicine, 2019, 381, 1023-1034. | 13.9 | 180 |
| 47 | Cardiovascular events in patients with COPD: TORCH Study results. Thorax, 2010, 65, 719-725. | 2.7 | 177 |
| 48 | Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940. | 6.3 | 176 |
| 49 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Archivos De Bronconeumologia, 2017, 53, 128-149. | 0.4 | 173 |
| 50 | Determinants of poor 6-min walking distance in patients with COPD: The ECLIPSE cohort. Respiratory Medicine, 2010, 104, 849-857. | 1.3 | 171 |
| 51 | Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax, 2007, 62, 595-601. | 2.7 | 170 |
| 52 | Addressing the Complexity of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1129-1137. | 2.5 | 166 |
| 53 | An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, e4-e27. | 2.5 | 166 |
| 54 | Inhaled corticosteroids in COPD: friend or foe?. European Respiratory Journal, 2018, 52, 1801219. | 3.1 | 166 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. European Respiratory Journal, 2013, 42, 636-646. | 3.1 | 164 |
| 56 | Impact and prevention of severe exacerbations of COPD: a review of the evidence. International Journal of COPD, 2017, Volume 12, 2891-2908. | 0.9 | 162 |
| 57 | Gene Expression Profiling of Human Lung Tissue from Smokers with Severe Emphysema. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 601-610. | 1.4 | 159 |
| 58 | Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 317-322. | 2.5 | 157 |
| 59 | Airway obstruction in never smokers: Results from the Third National Health and Nutrition Examination Survey. American Journal of Medicine, 2005, 118, 1364-1372. | 0.6 | 156 |
| 60 | Clinical Trial Design Considerations in Assessing Longâ€Term Functional Impacts of Tiotropium in COPD: The Uplift Trial. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2004, 1, 303-312. | 0.7 | 152 |
| 61 | Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax, 2014, 69, 718-723. | 2.7 | 151 |
| 62 | Predictors of mortality in COPD. Respiratory Medicine, 2010, 104, 773-779. | 1.3 | 145 |
| 63 | COPD comorbidities network. European Respiratory Journal, 2015, 46, 640-650. | 3.1 | 145 |
| 64 | Once-Daily Umeclidinium/Vilanterol 125/25 Î¼g Therapy in COPD. Chest, 2014, 145, 981-991. | 0.4 | 142 |
| 65 | An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Journal, 2015, 45, 879-905. | 3.1 | 138 |
| 66 | Should We View Chronic Obstructive Pulmonary Disease Differently after ECLIPSE?. A Clinical Perspective from the Study Team. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1022-1030. | 2.5 | 130 |
| 67 | Markers of disease severity in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics, 2006, 19, 189-199. | 1.1 | 127 |
| 68 | C-Reactive Protein Levels and Survival in Patients With Moderate to Very Severe COPD. Chest, 2008, 133, 1336-1343. | 0.4 | 127 |
| 69 | Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis. Annals of the American Thoracic Society, 2015, 12, 303-312. | 1.5 | 126 |
| 70 | Biological Lung Volume Reduction. Chest, 2007, 131, 1108-1113. | 0.4 | 125 |
| 71 | Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respiratory Medicine,the, 2015, 3, 443-450. | 5.2 | 125 |
| 72 | Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. European Respiratory Journal, 2017, 50, 1701162. | 3.1 | 122 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1251-1258. | 2.5 | 121 |
| 74 | Distribution and Prognostic Validity of the New Global Initiative for Chronic Obstructive Lung Disease Grading Classification. Chest, 2013, 143, 694-702. | 0.4 | 120 |
| 75 | From GOLD 0 to Pre-COPD. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 414-423. | 2.5 | 119 |
| 76 | Systemic Cytokines, Clinical and Physiological Changes in Patients Hospitalized for Exacerbation of COPD. Chest, 2007, 131, 37-43. | 0.4 | 117 |
| 77 | Predictors of Survival in COPD: More than Just the FEV1. Respiratory Medicine, 2008, 102, S27-S35. | 1.3 | 117 |
| 78 | Genome-Wide Association Analysis of Blood Biomarkers in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1238-1247. | 2.5 | 117 |
| 79 | Prediction of risk of COPD exacerbations by the BODE index. Respiratory Medicine, 2009, 103, 373-378. | 1.3 | 116 |
| 80 | Protective role for club cell secretory protein-16 (CC16) in the development of COPD. European Respiratory Journal, 2015, 45, 1544-1556. | 3.1 | 115 |
| 81 | Longitudinal Change in the BODE Index Predicts Mortality in Severe Emphysema. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 491-499. | 2.5 | 114 |
| 82 | Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1000-1011. | 2.5 | 111 |
| 83 | Update on the Management of COPD. Chest, 2008, 133, 1451-1462. | 0.4 | 103 |
| 84 | Gender associated differences in determinants of quality of life in patients with COPD: a case series study. Health and Quality of Life Outcomes, 2006, 4, 72. | 1.0 | 98 |
| 85 | Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine, 2011, 105, 580-587. | 1.3 | 96 |
| 86 | Benefits of Long-Term Pulmonary Rehabilitation Maintenance Program in Patients with Severe Chronic Obstructive Pulmonary Disease. Three-Year Follow-up. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 622-629. | 2.5 | 94 |
| 87 | Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1195-1204. | 2.5 | 94 |
| 88 | Multicomponent indices to predict survival in COPD: the COCOMICS study. European Respiratory Journal, 2013, 42, 323-332. | 3.1 | 93 |
| 89 | COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series). Pulmonary Circulation, 2018, 8, 1-18. | 0.8 | 90 |
| 90 | B Cellâ€“Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 695-705. | 2.5 | 89 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e74-e87. | 2.5 | 87 |
| 92 | COPD: time to improve its taxonomy?. ERJ Open Research, 2018, 4, 00132-2017. | 1.1 | 84 |
| 93 | The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1483-1493. | 2.5 | 83 |
| 94 | Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax, 2014, 69, 799-804. | 2.7 | 82 |
| 95 | The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. European Respiratory Journal, 2013, 41, 1017-1022. | 3.1 | 81 |
| 96 | Bronchodilator Reversibility in COPD. Chest, 2011, 140, 1055-1063. | 0.4 | 80 |
| 97 | Bias due to withdrawal in longâ€term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal, 2011, 5, 44-49. | 0.6 | 78 |
| 98 | What does endotyping mean for treatment in chronic obstructive pulmonary disease?. Lancet, The, 2017, 390, 980-987. | 6.3 | 78 |
| 99 | Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respiratory Medicine, 2015, 109, 1138-1146. | 1.3 | 77 |
| 100 | Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respiratory Medicine,the, 2021, 9, 1288-1298. | 5.2 | 75 |
| 101 | DNA methylation profiling in human lung tissue identifies genes associated with COPD. Epigenetics, 2016, 11, 730-739. | 1.3 | 73 |
| 102 | Microalbuminuria and Hypoxemia in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1004-1010. | 2.5 | 72 |
| 103 | An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Review, 2015, 24, 159-172. | 3.0 | 72 |
| 104 | Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Preâ€“Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 275-287. | 2.5 | 72 |
| 105 | Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort. PLoS ONE, 2018, 13, e0193143. | 1.1 | 70 |
| 106 | Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respiratory Medicine,the, 2020, 8, 158-170. | 5.2 | 69 |
| 107 | Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFTÂ® trial. Respiratory Medicine, 2010, 104, 1495-1504. | 1.3 | 68 |
| 108 | The COPD Biomarker Qualification Consortium (CBQC). COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 367-377. | 0.7 | 67 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. Respirology, 2021, 26, 532-551. | 1.3 | 67 |
| 110 | Itâ€™s more than low BMI: prevalence of cachexia and associated mortality in COPD. Respiratory Research, 2019, 20, 100. | 1.4 | 66 |
| 111 | Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respiratory Care, 2006, 51, 1120-4. | 0.8 | 66 |
| 112 | Deterioration of Limb Muscle Function during Acute Exacerbation of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 433-449. | 2.5 | 64 |
| 113 | Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on Grouping and Outcomes. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 463-469. | 2.5 | 63 |
| 114 | Machine Learning and Prediction of All-Cause Mortality in COPD. Chest, 2020, 158, 952-964. | 0.4 | 62 |
| 115 | Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease. Respiratory Research, 2007, 8, 18. | 1.4 | 61 |
| 116 | Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research, 2011, 12, 71. | 1.4 | 60 |
| 117 | Rapid Lung Function Decline in Smokers Is a Risk Factor for COPD and Is Attenuated by Angiotensin-Converting Enzyme Inhibitor Use. Chest, 2014, 145, 695-703. | 0.4 | 60 |
| 118 | Club Cell Protein 16 (CC16) Augmentation: A Potential Disease-modifying Approach for Chronic Obstructive Pulmonary Disease (COPD). Expert Opinion on Therapeutic Targets, 2016, 20, 869-883. | 1.5 | 60 |
| 119 | Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. European Respiratory Journal, 2018, 51, 1702146. | 3.1 | 60 |
| 120 | Ventilatory Drive at Rest and Perception of Exertional Dyspnea in Severe COPD. Chest, 1999, 115, 1293-1300. | 0.4 | 59 |
| 121 | Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respiratory Medicine, 2005, 99, 1546-1554. | 1.3 | 59 |
| 122 | Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. European Respiratory Journal, 2014, 44, 324-331. | 3.1 | 57 |
| 123 | Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. International Journal of COPD, 2018, Volume 13, 3971-3981. | 0.9 | 56 |
| 124 | Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO. Chest, 2016, 149, 936-942. | 0.4 | 55 |
| 125 | Roger S. Mitchell Lecture. Chronic Obstructive Pulmonary Disease Phenotypes and Their Clinical Relevance. Proceedings of the American Thoracic Society, 2006, 3, 461-465. | 3.5 | 54 |
| 126 | Lung Volume Reduction Therapies for Advanced Emphysema. Chest, 2010, 138, 407-417. | 0.4 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Prognostic assessment in COPD: Health related quality of life and the BODE index. Respiratory Medicine, 2011, 105, 916-921. | 1.3 | 53 |
| 128 | Handgrip weakness and mortality risk in COPD: a multicentre analysis. Thorax, 2016, 71, 86-87. | 2.7 | 53 |
| 129 | Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations. Thorax, 2017, 72, 117-121. | 2.7 | 53 |
| 130 | Effect of a single exacerbation on decline in lung function in COPD. Respiratory Medicine, 2017, 128, 85-91. | 1.3 | 53 |
| 131 | A simple algorithm for the identification of clinical COPD phenotypes. European Respiratory Journal, 2017, 50, 1701034. | 3.1 | 53 |
| 132 | Executive Summary. Chest, 2015, 147, 883-893. | 0.4 | 51 |
| 133 | Differences in Cardiopulmonary Exercise Test Results by American Thoracic Society/European Respiratory Society-Global Initiative for Chronic Obstructive Lung Disease Stage Categories and Gender. Chest, 2007, 132, 1204-1211. | 0.4 | 50 |
| 134 | Genome-Wide Association Analysis of Body Mass in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 304-310. | 1.4 | 50 |
| 135 | Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: A pilot study. Respiratory Medicine, 2013, 107, 702-707. | 1.3 | 50 |
| 136 | Sex differences between women and men with COPD: A new analysis of the 3CIA study. Respiratory Medicine, 2020, 171, 106105. | 1.3 | 50 |
| 137 | Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 881-888. | 2.5 | 49 |
| 138 | Metformin: Experimental and Clinical Evidence for a Potential Role in Emphysema Treatment. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 651-666. | 2.5 | 49 |
| 139 | Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive PulmonaryÂDisease. Journal of the American College of Cardiology, 2018, 72, 1126-1137. | 1.2 | 48 |
| 140 | Chronic Obstructive Pulmonary Disease: From Unjustified Nihilism to Evidence-based Optimism. Proceedings of the American Thoracic Society, 2006, 3, 58-65. | 3.5 | 47 |
| 141 | Sexually-dimorphic targeting of functionally-related genes in COPD. BMC Systems Biology, 2014, 8, 118. | 3.0 | 47 |
| 142 | Point: Should We Abandon FEV 1 /FVC <0.70 To Detect Airway Obstruction? No. Chest, 2010, 138, 1037-1040. | 0.4 | 46 |
| 143 | Changes in Body Composition in Patients with Chronic Obstructive Pulmonary Disease: Do They Influence Patient-Related Outcomes?. Annals of Nutrition and Metabolism, 2013, 63, 239-247. | 1.0 | 46 |
| 144 | Telomere shortening and accelerated aging in COPD: findings from the BODE cohort. Respiratory Research, 2017, 18, 59. | 1.4 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 47-55. | 2.5 | 46 |
| 146 | Gender Differences in Plasma Biomarker Levels in a Cohort of COPD Patients: A Pilot Study. PLoS ONE, 2011, 6, e16021. | 1.1 | 44 |
| 147 | Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology, 2011, 16, 825-835. | 1.3 | 43 |
| 148 | Opportunities and Challenges in the Genetics of COPD 2010: An International COPD Genetics Conference Report. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011, 8, 121-135. | 0.7 | 43 |
| 149 | Perception of symptoms and quality of life – comparison of patients’ and physicians’ views in the COPD MIRROR study. International Journal of COPD, 2017, Volume 12, 2189-2196. | 0.9 | 43 |
| 150 | It is time for the world to take COPD seriously: a statement from the GOLD board of directors. European Respiratory Journal, 2019, 54, 1900914. | 3.1 | 43 |
| 151 | Finding the Best Thresholds of FEV1 and Dyspnea to Predict 5-Year Survival in COPD Patients: The COCOMICS Study. PLoS ONE, 2014, 9, e89866. | 1.1 | 43 |
| 152 | Treadmill Endurance During 2-Year Treatment With Tiotropium in Patients With COPD. Chest, 2013, 144, 490-497. | 0.4 | 42 |
| 153 | Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 689-698. | 2.5 | 42 |
| 154 | Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart, 2017, 103, 1536-1542. | 1.2 | 41 |
| 155 | Natural history of COPD: gaps and opportunities. ERJ Open Research, 2017, 3, 00117-2017. | 1.1 | 40 |
| 156 | Multimorbidity in Patients with Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2020, 41, 405-419. | 0.8 | 38 |
| 157 | Comorbidity Distribution, Clinical Expression and Survival in COPD Patients with Different Body Mass Index. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2014, 1, 229-238. | 0.5 | 38 |
| 158 | Time to desaturation in the 6-min walking distance test predicts 24-hour oximetry in COPD patients with a PO2 between 60 and 70mmHg. Respiratory Medicine, 2008, 102, 1026-1032. | 1.3 | 37 |
| 159 | Longitudinal assessment in COPD patients: multidimensional variability and outcomes. European Respiratory Journal, 2014, 43, 745-753. | 3.1 | 37 |
| 160 | Prognostic assessment in COPD without lung function: the B-AE-D indices. European Respiratory Journal, 2016, 47, 1635-1644. | 3.1 | 37 |
| 161 | Spirometric variability in smokers: transitions in COPD diagnosis in a five-year longitudinal study. Respiratory Research, 2016, 17, 147. | 1.4 | 36 |
| 162 | The Expanding Role of Biomarkers in the Assessment of Smoking-Related Parenchymal Lung Diseases. Chest, 2012, 142, 1027-1034. | 0.4 | 35 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | <p>FEV<sub>1</sub> is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease</p>. International Journal of COPD, 2020, Volume 15, 1135-1142. | 0.9 | 35 |
| 164 | The Challenge of Controlling the COPD Epidemic: Unmet Needs. American Journal of Medicine, 2018, 131, 1-6. | 0.6 | 33 |
| 165 | Time for a change: anticipating the diagnosis and treatment of COPD. European Respiratory Journal, 2020, 56, 2002104. | 3.1 | 33 |
| 166 | Chronic Obstructive Pulmonary Disease and Lung Cancer. Proceedings of the American Thoracic Society, 2012, 9, 74-79. | 3.5 | 32 |
| 167 | A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clinical Therapeutics, 2003, 25, 542-557. | 1.1 | 31 |
| 168 | Predictors of Mortality in Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2007, 28, 515-524. | 0.8 | 31 |
| 169 | A Novel Nonhuman Primate Model of Cigarette Smokeâ€“Induced Airway Disease. American Journal of Pathology, 2015, 185, 741-755. | 1.9 | 31 |
| 170 | Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of U.S. Studies. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2019, 6, 267-280. | 0.5 | 31 |
| 171 | Cough and Phlegm Are Important Predictors of Health Status in Smokers Without COPD. Chest, 2002, 121, 1427-1433. | 0.4 | 30 |
| 172 | Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. European Heart Journal, 2018, 39, 3128-3134. | 1.0 | 30 |
| 173 | Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. Respiratory Medicine, 2016, 119, 87-95. | 1.3 | 29 |
| 174 | Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. Respiratory Medicine, 2017, 131, 27-34. | 1.3 | 29 |
| 175 | Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation. Chest, 2017, 151, 358-365. | 0.4 | 29 |
| 176 | Use of Proteomic Patterns of Serum Biomarkers in Patients with Chronic Obstructive Pulmonary Disease: Correlation with Clinical Parameters. Proceedings of the American Thoracic Society, 2006, 3, 465-466. | 3.5 | 28 |
| 177 | Supplementation with QterÂ® and Creatine improves functional performance in COPD patients on long term oxygen therapy. Respiratory Medicine, 2018, 142, 86-93. | 1.3 | 28 |
| 178 | Change in the BODE Index Reflects Disease Modification in COPD. Chest, 2006, 129, 835-836. | 0.4 | 27 |
| 179 | Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine, 2011, 105, 1176-1188. | 1.3 | 27 |
| 180 | Cigarette smoking and response to inhaled corticosteroids in COPD. European Respiratory Journal, 2018, 51, 1701393. | 3.1 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2013, 7, 57-64. | 1.0 | 26 |
| 182 | Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 549. | 0.9 | 26 |
| 183 | Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. BMJ Open Respiratory Research, 2019, 6, e000431. | 1.2 | 26 |
| 184 | Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. European Respiratory Journal, 2021, 57, 2001339. | 3.1 | 26 |
| 185 | Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?. Current Drug Targets, 2013, 14, 177-191. | 1.0 | 26 |
| 186 | Chest <scp>CT</scp>â€assessed comorbidities and allâ€cause mortality risk in <scp>COPD</scp> patients in the <scp>BODE</scp> cohort. Respirology, 2022, 27, 286-293. | 1.3 | 26 |
| 187 | Lung Reduction Surgery in Severe COPD Decreases Central Drive and Ventilatory Response to CO2. Chest, 1997, 112, 902-906. | 0.4 | 25 |
| 188 | Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from the UPLIFT trial. Respiratory Research, 2011, 12, 129. | 1.4 | 25 |
| 189 | The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial. European Respiratory Journal, 2021, 57, 2003338. | 3.1 | 24 |
| 190 | Native American Ancestry, Lung Function, and COPD in Costa Ricans. Chest, 2014, 145, 704-710. | 0.4 | 23 |
| 191 | Precision medicine in COPD exacerbations. Lancet Respiratory Medicine,the, 2018, 6, 657-659. | 5.2 | 23 |
| 192 | Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis. Chronic Respiratory Disease, 2020, 17, 147997311990123. | 1.0 | 23 |
| 193 | Î²-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. Annals of the American Thoracic Society, 2018, 15, 608-614. | 1.5 | 22 |
| 194 | Plasma metabolomics and clinical predictors of survival differences in COPD patients. Respiratory Research, 2019, 20, 219. | 1.4 | 22 |
| 195 | Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD. Chest, 2021, 160, 872-878. | 0.4 | 22 |
| 196 | Airflow reversibility and long-term outcomes in patients with COPD without comorbidities. Respiratory Medicine, 2014, 108, 1180-1188. | 1.3 | 21 |
| 197 | Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. BMC Medicine, 2018, 16, 33. | 2.3 | 21 |
| 198 | Premature discontinuation during the UPLIFT study. Respiratory Medicine, 2011, 105, 1523-1530. | 1.3 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respiratory Research, 2012, 13, 66. | 1.4 | 20 |
| 200 | Epicardial Adipose Tissue in Patients with Chronic Obstructive Pulmonary Disease. PLoS ONE, 2013, 8, e65593. | 1.1 | 20 |
| 201 | The Course of Lung Function in Middle-aged Heavy Smokers: Incidence and Time to Early Onset of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1449-1451. | 2.5 | 20 |
| 202 | Low plasma CC16 levels in smokers are associated with a higher risk for chronic bronchitis. European Respiratory Journal, 2015, 46, 1501-1503. | 3.1 | 19 |
| 203 | Telomere length, COPD and emphysema as risk factors for lung cancer. European Respiratory Journal, 2017, 49, 1601521. | 3.1 | 19 |
| 204 | Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFTÂ® trial. Respiratory Research, 2018, 19, 196. | 1.4 | 19 |
| 205 | Pharmacological Therapy of COPD. Chest, 2018, 154, 1404-1415. | 0.4 | 19 |
| 206 | Spirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases. European Journal of Internal Medicine, 2021, 89, 3-9. | 1.0 | 19 |
| 207 | Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. Respiratory Medicine, 2013, 107, 1904-1911. | 1.3 | 18 |
| 208 | ValidaciÃ³n pronÃ³stica segÃºn los criterios de la GesEPOC 2017. Archivos De Bronconeumologia, 2019, 55, 409-413. | 0.4 | 18 |
| 209 | Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT. Annals of the American Thoracic Society, 2022, 19, 204-213. | 1.5 | 18 |
| 210 | Future perspectives in COPD. Respiratory Medicine, 2005, 99, S41-S48. | 1.3 | 17 |
| 211 | Obstructive Lung Disease in Mexican Americans and Non-Hispanic Whites. Chest, 2014, 145, 282-289. | 0.4 | 16 |
| 212 | Dissecting COPD exacerbations: time to rethink our definition. European Respiratory Journal, 2017, 50, 1701432. | 3.1 | 16 |
| 213 | The most beautiful COPD chart in the world: all together to end COPD!. European Respiratory Journal, 2019, 54, 1902047. | 3.1 | 16 |
| 214 | Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD. Chest, 2021, 160, 481-490. | 0.4 | 16 |
| 215 | The EXACT-Pro: Measuring Exacerbations of COPD. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 287-288. | 2.5 | 15 |
| 216 | Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. ERJ Open Research, 2021, 7, 00902-2020. | 1.1 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Identification of Barriers to Influenza Vaccination in Patients with Chronic Obstructive Pulmonary Disease: Analysis of the 2012 Behavioral Risk Factors Surveillance Survey. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2016, 3, 620-627. | 0.5 | 15 |
| 218 | Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Pulmonary Medicine, 2015, 15, 145. | 0.8 | 14 |
| 219 | Chronic Obstructive Pulmonary Disease in Hispanics. A 9-Year Update. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 15-21. | 2.5 | 14 |
| 220 | Pulmonary arterial enlargement predicts long-term survival in COPD patients. PLoS ONE, 2018, 13, e0195640. | 1.1 | 13 |
| 221 | Characterizing Functional Lung Heterogeneity in COPD Using Reference Equations for CT Scan-Measured Lobar Volumes. Chest, 2013, 143, 1607-1617. | 0.4 | 12 |
| 222 | Continuous fat-free mass decline in COPD: fact or fiction?. European Respiratory Journal, 2015, 46, 1496-1498. | 3.1 | 12 |
| 223 | Prognostic assessment of patients with COPD. Lancet, The, 2009, 374, 1885. | 6.3 | 11 |
| 224 | Assessment of five different guideline indication criteria for spirometry, including modified GOLD criteria, in order to detect COPD: data from 5,315 subjects in the PLATINO study. Npj Primary Care Respiratory Medicine, 2014, 24, 14075. | 1.1 | 11 |
| 225 | Clinical and prognostic heterogeneity of C and D GOLD groups. European Respiratory Journal, 2015, 46, 250-254. | 3.1 | 11 |
| 226 | Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study. International Journal of COPD, 2016, 11, 1217. | 0.9 | 11 |
| 227 | Simplificando las guÃas: los 10 mandamientos de la EPOC. Archivos De Bronconeumologia, 2016, 52, 179-180. | 0.4 | 11 |
| 228 | Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients. Respiratory Research, 2017, 18, 175. | 1.4 | 11 |
| 229 | Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. Annals of the American Thoracic Society, 2019, 16, 29-39. | 1.5 | 11 |
| 230 | ADAM15 expression is increased in lung CD8+ T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstruction. Respiratory Research, 2020, 21, 188. | 1.4 | 11 |
| 231 | International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 25-33. | 2.5 | 11 |
| 232 | Six-Minute Walking Distance in Women with COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011, 8, 300-305. | 0.7 | 10 |
| 233 | Is COPD a Progressive Disease? A Long Term Bode Cohort Observation. PLoS ONE, 2016, 11, e0151856. | 1.1 | 10 |
| 234 | Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. ERJ Open Research, 2020, 6, 00253-2020. | 1.1 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Optimal NIV Medicare Access Promotion: Patients With COPD. Chest, 2021, 160, e389-e397. | 0.4 | 10 |
| 236 | Pulmonary rehabilitation for COPD. Postgraduate Medicine, 1998, 103, 159-176. | 0.9 | 9 |
| 237 | The club cell and its protein, CC16: time to shine. Lancet Respiratory Medicine,the, 2013, 1, 757-759. | 5.2 | 9 |
| 238 | Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. Archivos De Bronconeumologia, 2021, 57, 36-41. | 0.4 | 9 |
| 239 | Executive Summary. Chest, 2021, 160, 1808-1821. | 0.4 | 9 |
| 240 | Predicting Mortality in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1298-1299. | 2.5 | 8 |
| 241 | Maximal Oxygen Uptakeâ€"Risk Predictor of NSCLC Resection in Patients With Comorbid Emphysema: Lessons From NETT. Seminars in Thoracic and Cardiovascular Surgery, 2015, 27, 225-231. | 0.4 | 8 |
| 242 | Differences in Health-Related Quality of Life Between New Mexican Hispanic and Non-Hispanic White Smokers. Chest, 2016, 150, 869-876. | 0.4 | 8 |
| 243 | Somatotypes trajectories during adulthood and their association with COPD phenotypes. ERJ Open Research, 2020, 6, 00122-2020. | 1.1 | 8 |
| 244 | Inhaler device feature preferences among patients with obstructive lung diseases. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 | 0.4 | 8 |
| 245 | Urgent need of a management plan for survivors of COVID-19. European Respiratory Journal, 2020, 55, 2000764. | 3.1 | 8 |
| 246 | External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 8-17. | 0.7 | 7 |
| 247 | Health effects of the Federal Bureau of Prisons tobacco ban. BMC Pulmonary Medicine, 2012, 12, 64. | 0.8 | 6 |
| 248 | Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFTÂ® trial. Respiratory Research, 2016, 17, 48. | 1.4 | 6 |
| 249 | Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-actingÎ²2-agonists. Journal of Medical Economics, 2016, 19, 11-20. | 1.0 | 6 |
| 250 | Â¿Es realmente la enfermedad pulmonar obstructiva crÃ³nica una enfermedad progresiva?. Archivos De Bronconeumologia, 2017, 53, 362-363. | 0.4 | 6 |
| 251 | Tabaquismo en pacientes con EPOC, Â¿un nuevo fenotipo clÃnico?. Archivos De Bronconeumologia, 2018, 54, 249-250. | 0.4 | 6 |
| 252 | Shorter telomeres in non-smoking patients with airflow limitation. Respiratory Medicine, 2018, 138, 123-128. | 1.3 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Using the Peripheral Blood Eosinophil Count to Manage Patients with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2019, 16, 301-303. | 1.5 | 6 |
| 254 | Smoking Pattern in Men and Women: A Possible Contributor to Sex Differences in Smoke-related Lung Diseases. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1048-1051. | 2.5 | 6 |
| 255 | Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. Archivos De Bronconeumologia, 2021, 57, 533-539. | 0.4 | 6 |
| 256 | Prevalence of paradoxical bronchoconstriction after inhaled albuterol. Respiratory Medicine, 2018, 141, 100-102. | 1.3 | 5 |
| 257 | The effect of emphysema on readmission and survival among smokers with heart failure. PLoS ONE, 2018, 13, e0201376. | 1.1 | 5 |
| 258 | Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment . International Journal of COPD, 2019, Volume 14, 1019-1031. | 0.9 | 5 |
| 259 | Methods for a Seamless Transition From Tracheostomy to Spontaneous Breathing in Patients With COVID-19. Respiratory Care, 2020, 65, 1773-1783. | 0.8 | 5 |
| 260 | Effects of Tiotropium on Exacerbations in Patients with COPD with Low or High Risk of Exacerbations: A Post-Hoc Analysis from the 4-Year UPLIFTÂ® Trial. Chronic Obstructive Pulmonary Diseases (Miami, Fla) Tj ETQq0 0 0 rgBT /Overlock 10 | 0.5 | 5 |
| 261 | COPD heterogeneity: gender differences in the multidimensional BODE index. International Journal of COPD, 2007, 2, 151-5. | 0.9 | 5 |
| 262 | New treatment strategies for COPD. Postgraduate Medicine, 2005, 117, 27-34. | 0.9 | 4 |
| 263 | COPD (confusion over proper diagnosis) in the zone of maximum uncertainty. European Respiratory Journal, 2015, 46, 1525-1526. | 3.1 | 4 |
| 264 | Recommendations for the early diagnosis of COPD: the AIMAR view. Multidisciplinary Respiratory Medicine, 2015, 10, 6. | 0.6 | 4 |
| 265 | The EASI model: A first integrative computational approximation to the natural history of COPD. PLoS ONE, 2017, 12, e0185502. | 1.1 | 4 |
| 266 | Long-Acting Î²-Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1641-1644. | 2.5 | 4 |
| 267 | Prognostic Validation Using GesEPOC 2017 Severity Criteria. Archivos De Bronconeumologia, 2019, 55, 409-413. | 0.4 | 4 |
| 268 | Impact of pre-enrolment medication use on clinical outcomes in SUMMIT. ERJ Open Research, 2019, 5, 00203-2018. | 1.1 | 4 |
| 269 | The Prevalence of Obstructive Lung Disease in a Lung Cancer Screening Cohort: Analysis of the National Lung Screening Trialâ€“American College of Radiology Image Network Cohort. Annals of the American Thoracic Society, 2019, 16, 641-644. | 1.5 | 4 |
| 270 | Pharmacotherapy Impacts on COPD Mortality. Archivos De Bronconeumologia, 2021, 57, 5-6. | 0.4 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Triple Therapy Is Also Effective in Real-World When Used in Chronic Obstructive Pulmonary Disease Patients Who Are Frequent Exacerbators. Respiration, 2021, 100, 93-95. | 1.2 | 4 |
| 272 | Comparison of arterial and venous blood biomarker levels in chronic obstructive pulmonary disease. F1000Research, 2013, 2, 114. | 0.8 | 4 |
| 273 | Women with chronic obstructive pulmonary disease: an emerging phenotype of the disease. Therapy: Open Access in Clinical Medicine, 2009, 6, 821-830. | 0.2 | 3 |
| 274 | Counterpoint: Should Storefront Clinics Provide Case Finding and Chronic Care for COPD? No. Chest, 2014, 145, 1193-1194. | 0.4 | 3 |
| 275 | Is the Blood Eosinophil Count a Useful Biomarker in COPD? The devil is in the Details!. Archivos De Bronconeumologia, 2017, 53, 415-416. | 0.4 | 3 |
| 276 | Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. Archivos De Bronconeumologia, 2021, 57, 36-41. | 0.4 | 3 |
| 277 | Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFTÂ® Randomized Controlled Trial. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2015, 2, 236-251. | 0.5 | 3 |
| 278 | Does Pharmacotherapy Reduce the Rate of Decline of Lung Function in COPD?. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 171-172. | 2.5 | 2 |
| 279 | The BODECOST Index (BCI): a composite index for assessing the impact of COPD in real life. Multidisciplinary Respiratory Medicine, 2016, 11, 10. | 0.6 | 2 |
| 280 | Documento de expertos del uso de broncodilatadores inhalados en monoterapia en el tratamiento de la EPOC estable leve-moderada. Archivos De Bronconeumologia, 2017, 53, 574-582. | 0.4 | 2 |
| 281 | Improving Our Aim: Targeting Therapy with Roflumilast in Patients with Severe and Very Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1242-1244. | 2.5 | 2 |
| 282 | Predictors of Nebulized Arformoterol Treatment: A Retrospective Analysis of Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease*. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 140-151. | 0.7 | 2 |
| 283 | Regional differences in rate of FEV1 decline in COPD: lessons from SUMMIT. European Respiratory Journal, 2019, 53, 1900278. | 3.1 | 2 |
| 284 | A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients . International Journal of COPD, 2020, Volume 15, 1801-1811. | 0.9 | 2 |
| 285 | Chronic Obstructive Pulmonary Disease in the Twenty-First Century. Clinics in Chest Medicine, 2020, 41, xv-xvii. | 0.8 | 2 |
| 286 | Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial. Respiratory Research, 2020, 21, 26. | 1.4 | 2 |
| 287 | Nocturnal Hypoxemia and CT Determined Pulmonary Artery Enlargement in Smokers. Journal of Clinical Medicine, 2021, 10, 489. | 1.0 | 2 |
| 288 | A 62-Year-Old Woman With Chronic Obstructive Pulmonary Disease. JAMA - Journal of the American Medical Association, 2003, 290, 2721. | 3.8 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Is the Blood Eosinophil Count a Useful Biomarker in COPD? The devil is in the Details!. Archivos De Bronconeumologia, 2017, 53, 415-416. | 0.4 | 1 |
| 290 | Rapid decline in lung function in healthy adults predicts incident excess urinary albumin excretion later in life. BMJ Open Respiratory Research, 2017, 4, e000194. | 1.2 | 1 |
| 291 | A Historical Perspective of Pulmonary Rehabilitation. , 2018, , 3-18. | | 1 |
| 292 | Reply to Voelkel: Cigarette Smoke Is an Endothelial Cell Toxin. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 274-275. | 2.5 | 1 |
| 293 | Functional Studies of Single-Nucleotide Polymorphisms Suggest Heterogeneity in Chronic Obstructive Pulmonary Disease due to Susceptibility of Different Cell Types. Annals of the American Thoracic Society, 2018, 15, S285-S285. | 1.5 | 1 |
| 294 | Targeting dyspnoea in patients with very severe COPD: Practical precision medicine. Respirology, 2018, 23, 1086-1087. | 1.3 | 1 |
| 295 | Muscle loss in <scp>COPD</scp>: An â€˜implodingâ€™ phenotype in need of therapies. Respirology, 2021, 26, 8-9. | 1.3 | 1 |
| 296 | Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. Archivos De Bronconeumologia, 2021, 57, 533-539. | 0.4 | 1 |
| 297 | The use of multidimensional indices. , 0, , 143-160. | | 1 |
| 298 | Network analysis of autopsy diagnoses: Insights into the â€œcause of deathâ€•from unbiased disease clustering. Journal of Pathology Informatics, 2018, 9, 35. | 0.8 | 1 |
| 299 | ANTES: Un aÃ±o despuÃ©s en la EPOC. Archivos De Bronconeumologia, 2022, 58, 291-294. | 0.4 | 1 |
| 300 | Pulmonary rehabilitation. Israel Medical Association Journal, 2003, 5, 443-8. | 0.1 | 1 |
| 301 | Selecting the Right Patient: The Achilles Heel of COPD Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1051-1052. | 2.5 | 1 |
| 302 | Upper Airway Diseases. , 0, , 513-527. | | 0 |
| 303 | Lung Volume Reduction in Patients with COPD: Physiological and Clinical Implications. Current Respiratory Medicine Reviews, 2008, 4, 312-320. | 0.1 | 0 |
| 304 | Effect of Pharmacotherapy on Rate of Decline of FEV1in the TORCH Study. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 426-427. | 2.5 | 0 |
| 305 | Preface. Medical Clinics of North America, 2012, 96, xi-xii. | 1.1 | 0 |
| 306 | Treatment of the Stable Patient with Chronic Obstructive Pulmonary Disease. , 2012, , 553-561. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Rebuttal From Dr Celli. Chest, 2014, 145, 1195-1196. | 0.4 | 0 |
| 308 | We must join forces in the battle against COPD. European Respiratory Journal, 2015, 46, 1528-1528. | 3.1 | 0 |
| 309 | Reply: Controlled Clinical Trials and Real-Life Experience with Pulmonary Rehabilitation. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 797-797. | 2.5 | 0 |
| 310 | Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2017, 53, 574-582. | 0.4 | 0 |
| 311 | Failure of Low-Dose Theophylline to Prevent Exacerbations in Patients With COPD. JAMA - Journal of the American Medical Association, 2018, 320, 1541. | 3.8 | 0 |
| 312 | Enriched Systemic Biomarkers in Symptomatic Unobstructed Smokers. Chest, 2019, 155, 886-887. | 0.4 | 0 |
| 313 | Report of the Barcelona Boston Lung Conference 2020. Open Respiratory Archives, 2020, 2, 141-142. | 0.0 | 0 |
| 314 | Reply to: Thomson, to Neder et al., and to Wouters. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 112. | 2.5 | 0 |
| 315 | In memorium, Claudio F. Donner, MD (1948â€“2021): respiratory medicine's impresario. Respiratory Medicine, 2021, 188, 106616. | 1.3 | 0 |
| 316 | Comorbidities in Patients With Chronic Obstructive Pulmonary Disease. , 2022, , 663-674. | | 0 |
| 317 | Management Guidelines for Chronic Obstructive Pulmonary Disease. , 2011, , 81-98. | | 0 |
| 318 | Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2019, 6, 297-307. | 0.5 | 0 |
| 319 | The 7 Cardinal Sins of COPD in Spain. Archivos De Bronconeumologia, 2022, 58, 498-503. | 0.4 | 0 |
| 320 | Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCS Trial. International Journal of COPD, 2022, Volume 17, 273-282. | 0.9 | 0 |
| 321 | Novel concepts in the pharmacotherapy of chronic obstructive pulmonary disease. Pneumonologia I Alergologia Polska, 2009, 77, 82-90. | 0.6 | 0 |
| 322 | Reply to Bhatt and Ramakrishnan, et al.. American Journal of Respiratory and Critical Care Medicine, 2022, , . | 2.5 | 0 |
| 323 | [Translated article] The ANTES Program in COPD: First Year. Archivos De Bronconeumologia, 2022, 58, T291-T294. | 0.4 | 0 |